Oncology Dose optimisation in oncology: Insights from AACR 2026 and i... Five years after its launch, the FDA’s Project Optimus remained a key theme in discussions at AACR 2026.
Oncology AACR 2025: New modalities and remaining challenges Explore the latest advancements and challenges in ADC therapy at AACR 2025: New modalities and remaining challenges
News AACR 2025: Quintet of investigational oncological drugs puts... Ascentage Pharma, specialising in haematological malignancies, has presented results from five preclinical studies at AACR 2025.
News AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncol... Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for MaaT034 at AACR 2025.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
